<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2277">
  <stage>Registered</stage>
  <submitdate>5/03/2009</submitdate>
  <approvaldate>5/03/2009</approvaldate>
  <nctid>NCT00857168</nctid>
  <trial_identification>
    <studytitle>To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion</studytitle>
    <scientifictitle>A Phase I Trial to Determine the Impact of Application of Antiperspirant and Deodorant as Well as Washing the Application Site, on the Pharmacokinetics of Testosterone Following Single Dose Applications of 2% Testosterone MD-Lotion® (Cutaneous Solution)</scientifictitle>
    <utrn />
    <trialacronym>MTE10</trialacronym>
    <secondaryid>MTE10</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypogonadism</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Testosterone MD-Lotion

Active Comparator: Group 1 - 

Active Comparator: Group 2 - 

Active Comparator: Group 3 - 

Active Comparator: Group 4 - 

Active Comparator: Group 5 - 

Active Comparator: Group 6 - 


Treatment: drugs: Testosterone MD-Lotion


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the impact of application of antiperspirant and deodorant on absorption of testosterone, when applied pre-application of Testosterone MD-Lotion® (cutaneous solution). Also to evaluate the impact of washing.</outcome>
      <timepoint>April 2009</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the safety and tolerability of Testosterone MD-Lotion® (cutaneous solution) following single dose application.</outcome>
      <timepoint>April 2009</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy premenopausal female subjects =18 and =45 years of age with qualifying general
             medical health.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Disqualifying concurrent condition or allergy/sensitivity to testosterone replacement
             therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>QPharm Pty Ltd - Brisbane</hospital>
    <postcode> - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Acrux DDS Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Testosterone replacement treatment is the most effective way of treating hypogonadism in men.

      Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study
      will evaluate the impact of application of antiperspirant and deodorant on absorption of
      testosterone, when applied pre-application of Testosterone MD-Lotion® (cutaneous solution).

      The study also aim to evaluate the impact of washing the application site on the absorption
      of testosterone, when washed post-application of Testosterone MD-Lotion® (cutaneous
      solution).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00857168</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tina Soulis, PhD</name>
      <address>Acrux Pharma Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>